We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » 483 Roundup: FDA Observes Lapses at Four Drug Facilities
483 Roundup: FDA Observes Lapses at Four Drug Facilities
The FDA observed a variety of quality issues during inspections of four drug facilities, including inadequate environmental monitoring, reviews of batch records, non-microbial contamination and — in one case — the lack of a quality unit.